Navigation Links
S1 Pharmaceuticals Appoints Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to Its Scientific Advisory Board
Date:10/24/2011

JERSEY CITY, N.J., Oct. 24, 2011 /PRNewswire/ -- S1 Pharmaceuticals, Inc. (S1) today announced that it has appointed Robert Taylor Segraves, MD, PhD, and Robert Pyke, MD, PhD to its Scientific Advisory Board.  Dr. Segraves and Dr. Pyke will help guide the clinical development of S1's lead product, Lorexys, as it prepares for Phase I clinical trials.

"We are pleased to be able to attract such knowledgeable and prominent individuals as Segraves and Pyke to participate as members of our Scientific Advisory Board," stated Nicolas G. Sitchon, MA, MBA, Chief Executive Officer of S1 Pharmaceuticals.  "The formation of a distinguished advisory board to provide medical, clinical, and strategic guidance to the Company marks the next step in the evolution of our Lorexys clinical development program."

Dr. Segraves is a professor of psychiatry at Case Western Reserve School of Medicine.  Among his scientific interests are the treatment of sexual disorders, the co-morbidity of sexual dysfunction with anxiety and depressive disorders, sexual side effects of pharmacological agents, and pharmacotherapy of sexual disorders.  Dr. Segraves has authored over 200 publications in the area of human sexuality, numerous international presentations, and five texts.  He sits on the editorial board of the International Journal of Impotence Research and is the current editor of the Journal of Sex and Marital Therapy.  Dr. Segraves obtained his M.D. from Vanderbilt University, his PhD from the University of London, and completed his residency in psychiatry at the University of Chicago.

Dr. Pyke served as Director of Clinical Research at Boehringer Ingelheim Pharmaceuticals where he led the Flibanserin Worldwide premenopausal HSDD clinical program that ended in October 2010.  Dr. Pyke has a distinguished career of leading drug after drug to FDA approval with Parke-Davis, Bristol-Myers Squibb, and Upjohn.  He has continued his clinical practice treating anxiety, depression, and substance abuse.  Dr. Pyke is a member of numerous societies, including the International Society for the Study of Women's Sexual Health.  He completed his Ph.D. at the University of Wisconsin, Madison, obtained his M.D. at the University of Miami, and completed his medical training in Internal Medicine at the University of Michigan.

"I look forward to serving on the advisory board for this promising potential therapy," stated Pyke. "The field of sexual health is ever evolving and it's exciting to join a company that is on the leading edge of this evolution."

About S1 Pharmaceuticals, Inc.
S1 is an early-stage biopharmaceutical company developing therapeutic solutions for disorders of Women's Sexual Health.  The most common type of Female Sexual Dysfunction (FSD) is a loss of libido and lack of sexual interest known as Hypoactive Sexual Desire Disorder (HSDD).  S1 is developing its lead product, Lorexys, as an oral drug and will seek to demonstrate that Lorexys can be the first safe and effective treatment approved by the FDA for HSDD in women.

Contact:
press@s1pharma.com
(201) 839-0941


'/>"/>
SOURCE S1 Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals to Announce 2011 Third Quarter Results on November 3, 2011
2. Cumberland Pharmaceuticals Ranks as one of the Fastest Growing Companies in North America on Deloittes 2011 Technology Fast 500™
3. Onyx Pharmaceuticals Announces Third Quarter 2011 Financial Results Teleconference and Webcast
4. Jazz Pharmaceuticals Announces Third Quarter 2011 Results Conference Call on November 1
5. Arrien Pharmaceuticals Appoints Dr. Philip LoGrasso to its Scientific Advisory Board for CNS/Neurodegenerative Diseases
6. Critical Alerts For Intel, Mosaic, Deckers, Foot Locker, and Jazz Pharmaceuticals Released By Seven Summits Research
7. Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl
8. Amylin Pharmaceuticals Reports Third Quarter Financial Results
9. CureFAKtor Pharmaceuticals to Present at 10th Annual BIO Investor Forum
10. ADVENTRX Pharmaceuticals to Present at the 10th Annual BIOInvestor Forum Conference on October 26
11. Rock Creek Pharmaceuticals Announces Expanded International Shipping Options for Anatabloc™, Physician Conferences on Anatabine Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 ... Surgical drainage devices are tubes used to remove excess ... include, blood, serum, pus, urine, bile or lymph. Surgical ... types of surgery such as orthopedics surgery, cardiovascular surgery, ... device is prophylactic post-surgery to prevent accumulation of fluid ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ... and HR decision-makers are preparing for how his administration could impact the employee ... insight into what changes are most likely to make it through Congress. His ...
(Date:4/25/2017)... Las Vegas, NV (PRWEB) , ... April 25, ... ... teeth can now choose a modern procedure that achieves results in a fraction ... orthodontist in Las Vegas, NV, with Significance Dental Specialists, now offers this ...
(Date:4/25/2017)... ... April 25, 2017 , ... Buyers and sellers in the ... dispensaries and head shops –can’t help but be heartened by the industry’s current surge. ... odor aptly described as “skunk smell.” At last they can simply, safely and ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... There is ... Regional Hospital, according to a special report in the May issue of Consumer Reports ... its highest quality ranking for results achieved during and after coronary bypass and aortic ...
(Date:4/24/2017)... ... 2017 , ... LG CNS Healthcare Solutions debuted the next ... Telehealth 2.0, the American Telemedicine Association’s national conference. , BYOD has been added ... pre-programmed tablet in a remarkably easy-to-use kit for patients. “BYOD is the next ...
Breaking Medicine News(10 mins):